Costly Information in Firm Transformation, Exit, or Persistent Failure
28 Pages Posted: 11 Sep 1996 Last revised: 29 Sep 2022
Date Written: May 1996
Abstract
Firms invest differentially in the intellectual human capital required to recognize, evaluate, and utilize technological breakthroughs occurring outside the firm. Such differential investment has been crucial in explaining which incumbent pharmaceutical firms have successfully transformed their technological identities in response to the biotechnological revolution and which are threatened by persistent low performance. While all incumbent firms lagged the dedicated new biotechnology firms in adopting the new drug-discovery technology, firms with higher R&D expenditures before the biotech revolution were more likely to successfully adopt the new techniques and likely to do so earlier. Failure to adopt the new techniques was associated with lower performance compared to firms adopting more fully and faster.
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
How Do Value Creation and Competition Determine Whether a Firm Appropriates Value?
By Glenn Macdonald and Michael D. Ryall
-
Research in Cognition and Strategy: Reflections on Two Decades of Progress and a Look to the Future
By Sarah Kaplan
-
Causal Ambiguity, Operating Complexity and Strong Capability-Based Advantages